ATE147977T1 - Verwendung von kompetitiven nmda- rezeptorantagonisten zur behandlung der harninkontinenz - Google Patents

Verwendung von kompetitiven nmda- rezeptorantagonisten zur behandlung der harninkontinenz

Info

Publication number
ATE147977T1
ATE147977T1 AT93305762T AT93305762T ATE147977T1 AT E147977 T1 ATE147977 T1 AT E147977T1 AT 93305762 T AT93305762 T AT 93305762T AT 93305762 T AT93305762 T AT 93305762T AT E147977 T1 ATE147977 T1 AT E147977T1
Authority
AT
Austria
Prior art keywords
urinary incontinence
treatment
receptor antagonists
competitive nmda
nmda receptor
Prior art date
Application number
AT93305762T
Other languages
English (en)
Inventor
Karl Bruce Thor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE147977T1 publication Critical patent/ATE147977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT93305762T 1992-07-24 1993-07-22 Verwendung von kompetitiven nmda- rezeptorantagonisten zur behandlung der harninkontinenz ATE147977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/919,480 US5192751A (en) 1992-07-24 1992-07-24 Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
ATE147977T1 true ATE147977T1 (de) 1997-02-15

Family

ID=25442169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93305762T ATE147977T1 (de) 1992-07-24 1993-07-22 Verwendung von kompetitiven nmda- rezeptorantagonisten zur behandlung der harninkontinenz

Country Status (9)

Country Link
US (1) US5192751A (de)
EP (1) EP0580429B1 (de)
JP (1) JPH06183975A (de)
AT (1) ATE147977T1 (de)
CA (1) CA2100950A1 (de)
DE (1) DE69307617T2 (de)
DK (1) DK0580429T3 (de)
ES (1) ES2096867T3 (de)
GR (1) GR3023032T3 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
EP0741724B1 (de) * 1994-01-31 1999-08-11 Pfizer Inc. Neuroprotektive chroman verbindungen
NZ284852A (en) * 1994-08-18 1998-06-26 Pfizer 3-(piperidin-1-yl)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidin-1-yl) alkanol derivatives; medicaments; used as a neuroprotective agent
ES2214532T3 (es) 1995-03-03 2004-09-16 Endo Pharmaceuticals Inc. Uso de dextrorfano o dextrometorfano para el tratamiento de la incontinencia urinaria.
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW427978B (en) * 1996-02-03 2001-04-01 Hoffmann La Roche Tetrahydroisoquinoline derivatives
US5880138A (en) * 1996-10-01 1999-03-09 Eli Lilly And Company NMDA receptor selective antagonists
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
CA2505930C (en) 1997-07-15 2008-01-29 Richard A. Schmidt Use of botulinum toxin in the preparation of a pharmaceutical composition for treating urinary retention
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
EA011094B1 (ru) * 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
NZ582917A (en) * 2007-06-29 2013-01-25 Univ Emory Nmda receptor antagonists for neuroprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
ES2096867T3 (es) 1997-03-16
US5192751A (en) 1993-03-09
DE69307617D1 (de) 1997-03-06
DE69307617T2 (de) 1997-05-28
CA2100950A1 (en) 1994-01-25
EP0580429B1 (de) 1997-01-22
EP0580429A1 (de) 1994-01-26
DK0580429T3 (da) 1997-07-14
GR3023032T3 (en) 1997-07-30
JPH06183975A (ja) 1994-07-05

Similar Documents

Publication Publication Date Title
DE69307617T2 (de) Verwendung von Kompetitiven NMDA-Rezeptorantagonisten zur Behandlung der Harninkontinenz
DE69328981T2 (de) Verfahren zur Behandlung von hyperproliferaktiven Gefässerkrankungen unter Verwendung von Rapamycin, eventuell in Kombination mit Mykophenolsäure
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
PT932402E (pt) Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia
ATE350060T1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
DE69725484D1 (de) Vorrichtung zur Behandlung von Harninkontinenz
ATE142107T1 (de) Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69126701D1 (de) Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
DE69227571D1 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivität und zur behandlung von tumoren
DE69229442T2 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE103182T1 (de) Antimikrobielle zusammensetzungen.
ATE145911T1 (de) Inositol-phosphat-analog als kalzium- antagonistische substanz
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE59000985D1 (de) Verwendung von monocarbonsaeurepolyoxyalkylester -sulfonaten als schaumarme textilbehandlungsmittel.
DE69215191T2 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz
DK0379308T3 (da) Fremgangsmåde til selektivt at blokere 5HT2 receptorer
ATE102828T1 (de) Verwendung von calciumantagonisten fuer die behandlung von narben.